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Abstract 
Several effective anticancer therapeutic drugs containing coumarin nucleus. Thus, some coumarin derivatives 3-
22 were prepared.  The structures of these compounds established on the basis of  spectral data as IR,  1HNMR,  
13CNMR  and  MS.  Moreover, the optimization geometries for compounds 3-13,15,17a,18a,19-22 were 
discussed using PM3 base set. The molecular docking simulations into the active site of COX-2 were 
performed,  and  showed  that,   some  compounds  7,8, 11,13, and 20 are suitable  inhibitor  against COX-2,  
and  can  used  as  anti-cancer  drugs. The compounds 7,8, 11,13  and 20 were evaluated on 50µg dose,  against 
Ehrlich solid  carcinoma (EAC) tumor model in Swiss albino mice . The activity was assessed using survival 
time and average increase in body weight, and showed that, these compounds are effective in reducing solid 
tumor mass EAC cells, and 20 showed highest potency.  In silico, The ADMET profiles showed that, these 7,8, 
11,13 and 20  compounds are good oral bioavailability, and are CNS active agents without marked health effects 
observed for rodent toxicity. 
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1. Introduction 
Cancer is a major public health [1],  which  known as metastasis [2-4]. The chemotherapy agent is primary 
strategy for treatment of tumor cell, which depending on poisoned cancer cell [5].  Non-steroidal anti-
inflammatory drugs (NSAIDs) are effective in different clinical setting, which widely employed with Patients 
suffering musculoskeletal and inflammatory diseases [6-9], and act as COX-2  inhibitors, through inhibiting the 
production of prostaglandins (PGs) [10-12]. The PGS level are increased in various tumor types, the 
inflammation plays a vital role in formation of tumor cell, and inhibit prostaglandin biosynthesis, which is 
responsible for the NSAIDs chemo preventive activity of [13-16]. Some famous marketing drugs (Strcture1) are 
suffering from gastrointestinal drawback [17-19]. Coumarin derivatives are a novel class of inhibitors of the 
carbonic anhydrase (CA) [20-22].  CA is a metalloenzymes family, which involved providing bicarbonate 
radical through an important physiological reaction [23-27]. The bicarbonate is important for formation tumor 
cell, reduction supplies of bicarbonate radical is suggested mechanism action of CA inhibitors (CAIs) [27]. 
Coumarin nucleus inhibit many isoforms CA I–CA XV, through the hydrolyzed coumarin nucleus to 2-
hydroxycinnamic acid, which bind with CA to form enzyme-inhibitor adduct [28-30]. 
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Strcture 1: Chemical strcture of commenly used markting bASIDS  
In addition, the hydrophobic amino acid derivatives especially containing amide and thioamide moieties possess 
diverse biological activities, as anti-inflammatory, anti-tumor and antimicrobial activities [7-9].  Hence, the 
present work aims to synthesis a novel class series of NSAIDs containing phenylalanine moiety acting as new 
anticancer agent targeting COX-2. The molecular docking was carried out, to predict the correct binding 
geometries for each ligand at the active site, followed by molecular modelling to identify the structural features  
of  these  new  Class. 
2. Experimental 
Melting points were taken on a Griffin melting point apparatus and are uncorrected. Thin layer chromatography 
(Rf) for analytical purposes were carried out on silica gel and developed. Benzidine, ninhydrin, and 
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hydroxamate tests used for detection reactions. The IR spectra of the compounds were recorded on a Perkin–
Elmer spectrophotometer model 1430 as potassium bromide pellets and frequencies are reported in cm-1. The 
NMR spectra were observed on a Varian Genini-300 MHz spectrometer and chemical shifts (δ) are in ppm. The 
mass spectra were recorded on a mass spectrometer HP model MS–QPL000EX (Shimadzu) at 70 eV. Elemental 
analyses (C,H,N) were carried out at the Microanalytical Centre of Cairo University, Giza, Egypt.  
Swiss albino mice were collected with age form 5 weeks to 7 weeks old,  and weighing 18-25 g from the 
National Cancer Institute (Cairo, Egypt) (NCIE), Cairo. The mice were kept in iron cages with sawdust and 
straw bedding that were changed once a week regularly. Standard mouse diet (recommended and prepared by 
the (NCIE) and water were given in adequate amounts. 
EAC cells were obtained from a line of EAC cells were obtained from the Cancer Biology Department of the 
National Cancer Institute (Cairo, Egypt). Body weight was balance by using Sartorious (500.0) g AC-DC 
CHARGER MODEL:MW79. 
Tumor volume was measured by VERNIER CALIPER 150X0.02 MM/6 XL/1000 and viable cell count was 
determined in a neubauer counting chamber. 
2.1. 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl chloride(2) 
The starting material (2) was prepared as mentioned by elhenawy and his colleagues [5]. 
2.2. 2-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)-3-phenylpropanoic acid (3) 
L-phenylalanine(L-Phe.)  was dissolved in 1N-NaOH, acid chloride (2; 0.01 mol) in acetone was added portion-
wise  during  1/2h at  10°C, the stirring was continued for  additional 3h., the  acetone  was  removed  by 
concentration  of  the  reaction  mixture under reduced pressure, water was added, and acidified with 1 N HCl to 
pH =5. The crude product (3) was filtered and re-crystallized from ethanol- water to give compound (3) as dark 
brown crystals. The crude product (3) was obtained in 80%yeild Rf = 0.85 (CH2-Phe/MeOH=3/1); M.P. = 90-
92Cº; IR (KBr cm-1) ν; 3405 cm-1(OH); 3201 cm-1(NH), 3090 (CH-arm.); 2973 cm-1(CH-ali); 1722, 1665 cm-1  
(C=O); 1H NMR (300 MHz, Chloroform)  δ= 10.40(s, 1H, OH-Carboxylic), 8.75(s,1H,OH-arm.), 7.21-6.7 
(m,9H, CH-Arm..), 5.55 (s,1H,NH), 4.94(m,1H,CH-Phe), 3.54(s,2H, CH2-ali.), 2.84 (d,2H,CH2-Phe); 
Anal./Calcd. for C20H17NO6 (367):C (65.37%), H(4.63%), N  (3.81%).   Found: C (65.39); H (4.66); N, (3.81). 
2.3. 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetylisothiocyanate (5) 
A mixture of compound (2, 0.01 mol) and  NH4SCN (0.01mole) in acetone (10ml.) was stirred  for 30 mins., the 
NH4Cl formed was filtered off, the filtrate containing compound (5) was used in other experiment without 
further purification.   
2.4. 2-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)-3-phenylpropanoyl chloride (6) 
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The compound (3; 0.01mol) in acetone (10 ml),  was heated with SOCl2 (0.01 mol.) for 30 mins. The acid 
chloride (6) formed,  which used directly in other experiments. 
2.5. 2-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)-3-phenyl-N-(4-sulfamoylphenyl)propanamide (7). 
Sulfanilamide (0.01mol) in acetone with  acid chloride (5; 0.01 mol), the reaction mixture was continued stirring 
for additional 3 hrs. at room temperature. After evaporation of the reaction mixture, the resulting crystals was 
filtered and recrystallized from benzene to give compound (7) as brownish red crystals. The compound was 
obtained in (75) % yield. Rf = 0.96 (CH2-Phe/MeOH=3/1); M.P. = 135-37Cº; IR (KBr cm-1 ) ν; 3353, cm-1 
(OH), 3242 cm-1 (NH2 , NH) ,2963 cm-1 (CH-ali), 1706 cm-1 (C=O),1621 cm-1 (CONH amide), 1335,1230 cm-1 
(SO2NH2 and SO2); MS (m/z, %) 522 (40.28%), Anal./Calcd. for C26H23N3O7S: C (59.86%), H (4.41%), N 
(8.05%). Found: C (59.88);  H (4.45); N, (8.06). 
2.6. Methyl-2-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamido)-3-phenyl-propanoate (8) 
The thionyl chloride (0.01 mol.) was added in dropwise  during 30 mins, to a stirred cold solution (5 °C) of 
compound (3;0.01 mol) in absolute methanol (30 ml.). The stirring was continued for additional 3 hrs. at (5 °C), 
the mixture was left for 24 hrs. at room temperature. The mixture was removed under reduced pressure, another 
portion of abs. methanol (10 ml.) was added and re-evaporated. The solid obtained was recrystallized from 
benzene to give Compound (8)  as brown crystal in 90 % yeild, Rf=0.87, (CH2-Phe/MeOH=3/1); M.P.146-48 
Cº ,IR (KBr cm-1 ) ν; 3275 cm-1 (NH), 2964 cm-1 (CH-ali..), 1721 cm-1 (C=O), 1619 cm-1 (CONH amide); 1H 
NMR (300 MHz, Chloroform) δ=8.60(s,1H,OH), 7.686.33(m, 9H, CH-arm..), 5.42 (s,1H,NH), 4.58(m,1H,CH-
Phe), 3.74(s,3H.CH3, OCH3), 3.32 (s,2H,CH2-ali..), 2.89 (d, 2H,CH2-Phe),13CNMR δ= 172.30,172.18, (2C, 
C=O),162.64-126.90(13C,C-arm..), 104.44(C-CH2.ali..), 53.84 (C-CH-Phe), 38.06(C-CH2-Phe), 37.63(C,CH3) 
MS (m/z, %) 381 (1.26%), Anal./Calcd for C21H19NO6: C(66.12%), H (4.98%), N(3.67%). Found: C (66.13); H 
(5.02); N, (3.67). 
2.7. N-(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)-2-(7-hydroxy-2-oxo-2H- chromen-4-yl)acetamide (9) 
The  methyl ester derivative   (8, 0.01 mol) was stirred in  ethanolic hydrazine hydrate solution(0.01mol)  for  
3hrs,    The crude product (9) was filtered, washed with water and  recrystallized from benzene to give desired   
compound (9) in 90% yield;Rf = 0.80, (CH2-Phe/MeOH=3/1); M.P.230-32 Cº ,IR (KBr cm-1 ) ν; 3405 cm-1 
(broad band, OH ,NH and NH2) ,2962,2931 cm-1 (CH-ali.), 1712, cm-1 (C=O), 1620 cm-1 (CONH amide), 1H 
NMR (300 MHz, Chloroform)  δ=10.94 (s,2H,NH2), 8.74-(s,1H,OH-Arm.), 7.90(s,1H, NH-Hyd.), 7.52-6.28 
(m,9H,CH-arm.), 5.66(s,1H,NH), 4.68 (s,1H,CH-Phe), 3.17 (s,2H,CH2-ali..), 2.90 (s,2H,CH2-Phe), MS (m/z, %) 
381(1.06%), Anal./Calcd for C20H19N3O5: C (62.97%), H (4.98%), N(11.01%).   Found: C (62.99); H (5.02); N, 
(11.02). 
2.8. N-(1-(2-formylhydrazinyl)-1-oxo-3-phenylpropan-2-yl)-2-(7-hydroxy-2-oxo-2H-chromen-4-
 yl)acetamide (10) 
Compound (9, 0.01mol) was heated under reflux with formic acid (0.01mol) for 10 hrs. The solid obtained after 
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cooling was filtered , and recrystallized from benzene to give compound (10) as brown crystals Yield: (65%); Rf 
= 0.83 (CH2-Phe/MeOH=3/1); M.P.=185-87°C; IR (KBr cm-1 ) ν; 3411 cm-1 (broad band, OH and NH), 2927 
cm-1 (CH-ali..),1621 cm-1 (CONH amide).;1H NMR (300 MHz, Chloroform)δ=9.59(2H,2NH-NHNH), 
9.43(s,1H,CH-CHO),8.24(s,1H,OH-arm.),7.66-6.60(m,9H,CH-arm.),5.45(s,1H,NH), 4.78 (s,1H,CH-Phe), 3.57 
(s,2H,CH2-ali..), 3.16 (d,2H, CH2-Phe); Anal./Calcd. for C21H19N3O6 (409): C (61.59%), H (4.64%), N 
(10.26%). Found: C (61.61); H (4.68); N, (10.26). 
2.9. N-(1-(2-acetylhydrazinyl)-1-oxo-3-phenylpropan-2-yl)-2-(7-hydroxy-2-oxo-2H-chromen-5-
 yl)acetamide (11) 
Compound (9, 0.01 mole) was refluxed with glacial acetic acid (20 ml.) for 3hrs., The solid obtained (11) after 
cooling was filtered and recrystallized from benzene to give compound  (11) as brown crystals ,Yield: (70 %); 
Rf = 0.80 °C., (CH2-Phe/MeOH=3/1);  M.P.=213-15°C; IR (KBr cm-1 ) ν; 3402 cm-1 (broad band, OH and NH), 
2959cm-1 cm-1 (CH-ali..), 1714 cm-1 (C=O), 1617cm-1 (CONH amide);1H NMR (300 MHz, Chloroform)  δ= 
10.59(s, 2H,NHNH), 9.36 (s, 1H, OH-arm.), 8.02-6.20 (m, 9H, CH-arm.) 5.43 (s, H, NH), 4.07 (1H,CH-L-Phe), 
3.47 (s,2H,CH2-ali..), 3.00(2H-CH2-L-Phe)2.06(s,3H,CH3); MS (m/z, %) 423  (67.96); Anal./Calcd.  for  
C22H21N3O6:  C  (62.41%),H(4.96%), N(9.92%).  Found: C(62.41%),  H (5.00%),  N(9.93%). 
2.10. N-(1-(5-(1-amino-2-phenylethyl)-1,3,4-oxadiazol-2-yl)-2-phenylethyl)-2-(7-hydroxy-2-oxo-2H 
 chromen-5-yl)acetamide (12)  
Compound (9; 0.01 mol),  L-phe. (0.01 mol) were dissolved in concentrated sulfuric acid(10 ml); the reaction 
mixture was stirred for 6h. at 80°C. The reaction mixture was cooled, poured into crushed ice, and neutralized 
with sodium carbonate to PH=7. The crude product (12) was filtered, washed with water, dried and the grey 
crystal was recrystallized by ethanol to obtain the pure product (14), as white crystal, in Yield: (85 %); Rf=0.89; 
(CH2-Phe/MeOH=3/1); M.P.=155-57°C; IR (KBr cm-1) ν; 3408 cm-1 (broad band, OH ,NH and NH2), 
2958,2927cm-1 (CH-ali.), 1714, cm-1 (C=O), 1620 cm-1 (CONH amide); MS (m/z, %) 509 (019%), Anal./Calcd.  
for C29H26N4O5 : C(68.22 %),  H (5.09 %), N  (10.98 %). Found: C (68.22); H (5.13); N, (10.97). 
2.11. N-(1-(2-carbamothioylhydrazinyl)1-oxo-3-phenylpropan-2-yl)-2-(7-hydroxy-2-oxo-2H- chromen-4-
 yl)acetamide (13) 
The hydrazide derivative (9; 0.01 mol.) was reacted with ammonium thiocyanate (0.01mol) in concentrated 
hydrochloric acid (20 ml). The reaction mixture was concentrated, and cool. The separated solid (13) was 
filtered, washed with water, and recrystallized from ethanol to give compound (13) as brown crystals; Yield: 
80%; Rf = 0.83(CH2-Phe/MeOH=3/1); M.P.=165-67°C, ; IR (KBr cm-1) ν; 3405cm-1 (broad band, OH ,NH and 
NH2) ,2960,2930 cm-1 (CH-ali.), 1698 cm-1(C=O), 1622 cm-1(CONH amide) 1239 cm-1 (C=S); 1H NMR (300 
MHz, Chloroform)  δ= 9.01(s,1H,OH), 8.95(s,2H,NH2),7.43-6.33 (m,11H,(2H,NH-NHNH)+(9H,CH-
arm.),5.63(s,1H,NH), 4.97(m,1H,CH-Phe),  3.19(s,2H, CH2-ali..) , 2.90 (d,2H,CH2-Phe); Anal./Calcd.  for 
C21H20N4O5S(440): C(57.25 %), H(4.54%),N(12.72%). Found: C (57.26); H (4.58); N, (12.72). 
2.12. 2(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-(2-phenyl-1-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-
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 ethyl)acetamide(15) 
Dissolve compounds (9; 0.01mol) in alcoholic  KOH, carbon disulfide (0.01 mol) was added to the reaction 
mixture. The reaction mixture was removed under reduced pressure; the residual salt was treated with water. 
The filtrate was neutralized to pH= 6 using dil. HCl, the residual material (15) was filtered, washed with water, 
dried, crystallized by ethanol as brown crystal;  in Yield 80 %; Rf = 0.88 (CH2-Phe/MeOH=3/1); M.P.=218-
20°C;  IR (KBr cm-1) ν; 3412 cm-1(broad band, OH and NH) ,2960cm-1  (CH-ali.), 1620 cm-1(CONH amide), 
1239 cm-1 (C=S); 1H NMR (300 MHz,Chloroform) δ= 8.62 (s,1H,OH), 7.66-6.47 (m,10H(1H,NH-
oxadiazolthione) + (9H,CH-arm.), 5.47 (s,1H,NH),4.83 (m,1H,CH-Phe),3.60 (s,2H,CH2-ali.), 3.20 (d, 2H,CH2-
Phe) ; Anal./Calcd. for  C21H17N3O5S (423):  C(59.56%),  H(4.01%), N(10.63%).  Found: C (59.57); H 
(4.05); N, (9.92). 
2.13. General procedures for synthesis N-(1-(2-aryylidenehydrazinyl)-1-oxo-3-phenyl -propan-2-yl)-2-(7-
 hydroxy-2-oxo-2H-chromen-4-yl)acetamide (17-c) 
The compound (9, 0.01mol) in glacial acetic acid (10 ml.) was heated with aromatic aldehydes (0.01 mole), the 
reaction mixtures were heated under reflux for 6-8 hrs. The solid products (17a-c) obtained after cooling, 
collected by filtration and recrystallized from ethanol to give compounds (17a-c), 
2.13.1. N-(1-(2-(2,4-dihydroxybenzylidene)hydrazinyl)-1-oxo-3-phenyl-propan-2-yl)-2-(7-hydroxy-2-oxo-
 2H-chromen-4-yl)acetamide (17a) 
Brownish red crystal; Yield 90 %; Rf = 0.85(CH2-Phe/MeOH=3/1);  M.P.=85-87°C;  IR (KBr cm-1  ) ν; 4434 cm-
1(broad band, OH ), 3353,3270 cm-1(NH) , 2921 cm-1  (CH-ali.), 1657 cm-1(C=O), 1597 cm-1(CONH amide); 1H 
NMR (300 MHz, Chloroform)  δ= 10.11-10.3 (t,3H,OH), 8.10 (s,1H,CH-N CH), 7.44-6.64 (m,13H,CH-arm.), 
6.41(1H,NH-NHNCHR),5.44(s,1H,NH-arm.), 4.85 (m,1H,CH-Phe), 3.07 (s,2H,CH2-ali.), 2.90 (d,2H,CH2-Phe); 
Anal./Calcd. for C27H23N3O7(501) :  C  (64.67 %), H (4.59%),  N(8.38%). Found: C(64.67); H (4.62); N, (8.38). 
2.13.2. N-(1-(2-(4-(dimethylamino)benzylidene)hydrazinyl)-1-oxo-3-phenyl-propan-2-yl)-2-(7-hydroxy-2-
 oxo-2H-chromen-4-yl)acetamide (17b) 
Brown crystal; Yield 73 %; Rf = 0.90 (CH2-Phe/MeOH=3/1);  M.P.=170-72°C;  IR (KBr cm-1) ν; 3385 cm-
1(broad band, OH, NH), 2931cm-1(CH-ali.), 1662 cm-1(C=O), 1601cm-1(CONH amide) 1H NMR (300 MHz, 
Chloroform)  δ= 10.82 (s,1H,OH), 8.19 (s,1H,CH-NCH),7.53-6.71(m,14H,CH-arm.),6.38(s,1H,NH-NHNCH), 
5.57(s, 1H,NH-arm.), 4.56 (s,2H,CH2.Phe.), 3.35 (s,2H,CH2-ali.), 3.00(s,6H,2CH3-N(CH3)2), 2.84 (2H,CH2-
Phe); Anal./Calcd. for C29H28N4O5 (512): C (67.69 %), H (5.46%), N (10.93%).   Found: C (67.96); H (5.51); N, 
(10.93) 
2.13.3. 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-(1-(2-(4-methox-ybenzyl-idene)hydrazinyl)-1-oxo-3-
 phenylpropan-2-yl) acetamide (17c) 
Brown crystal; Yield 65 %; Rf = 0.87 (CH2-Phe/MeOH=3/1);  M.P.=210-12°C;  IR (KBr cm-1) ν; 3391 cm-
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1(broad band,OH ,NH) , 2957,2926 cm-1(CH-ali.), 1698 cm-1(C=O), ,1620 cm-1(CONH amide); ),; 1H NMR 
(300 MHz, Chloroform); δ= 10.57 (s,1H,OH), 8.32 (s,1H,CH-N-CH), 7.60-6.65 (m,14H,CH-arm.), 5.86 
(1H,NH-NHNCHR),5.48(s,1H,NH-arm.),5.06 (s,2H,CH2. Phe.), 3.78(s,3H,CH3-OCH3), 3.19 (s,2H,CH2-ali.), 
3.17 (m,1H, CH-Phe), 2.96 (d,2H,CH2- Phe) MS (m/z, %) m/z 499 (46.51%) ,Anal./Calcd.for C28H25N3O6: C 
(67.33%),  H (5.01%), N  (8.41%). Found: C (67.33); H (5.04); N, (8.40). 
2.14. General procedures for synthesis of 4-(2-((1-(4-acetyl-5-aryl-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-
 phenylethyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-ylacetate (18a-c): 
The compounds (17a-c; 0.01 mol) were heated under reflux with acetic anhydride (15ml) for 10 hrs. The excess 
of acetic anhydride was decomposed with water (10ml), the reaction mixture was stirred for 30 mins. The 
separated solids were filtered, washed with water, dried and recrystallized from ethanol to give compounds (18 
a-c), respectively. 
2.14.1. 4-(2-((1-(4-acetyl-5-(2,4-dihydroxyphenyl)-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-phenylethyl)amino)-
 2-oxoethyl)-2-oxo-2H-chromen-7-yl acetate (18a) 
Brown crystal; Yield: 85 %; Rf = 0.90 (CH2-Phe/MeOH=3/1);  M.P.=221-23°C;  IR (KBr cm-1) ν; 3411cm-
1(NH) ,2959,2929 cm-1,(CH-ali.), 1621 cm-1(CONH amide) and; 1H NMR (300 MHz, Chloroform)  δ= 8.03-6.54 
(m, 14H, (1H,NH-arm.) +(13H,CH-arm.), 4.38(m,1H,CH-Phe), 3.02(s,2H,CH2.ali.), 2.82 (m, 8H,(6H,2(CH3)-
N(CH3)2) + (2H,CH2-Phe), 2.25 ,2.06 (s,6H,2CH3-COCH3);Anal./Calcd. for C31H27N3O9(585): C  (63.58%), H 
(4.61%), N (7.17%). Found: C (63.55); H (4.61); N, (7.18). 
2.14.2. 4-(2-(1-(4-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-phenylethylamino)-2-
 oxoethyl)-2-oxo-2H-chromen-7-yl acetate(18b) 
Brown crystal; Yield: 80 %; Rf = 0.86 (CH2-Phe/MeOH=3/1);  M.P.=90-92°C;  IR (KBr cm-1) ν; 3198 cm-
1(NH) , 2927cm-1(CH-ali.), 1764,1684 cm-1(C=O), 1604 cm-1(CONH amide); MS (m/z, %) 596 
(12.19%),Anal./Calcd.  for C33H32N4O7:  C  (66.44%),  H (9.39%). Found: C (66.43); H (5.41); N, (9.36). 
2.14.3. 4-(2-(1-(4-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-phenylethylamino)-2-
 oxoethyl)-2-oxo-2H-chromen-7-ylacetate (18c) 
Brown crystal; Yield: 76 %; Rf = 0.89 (CH2-Phe/MeOH=3/1);  M.P.=220-22°C;  IR (KBr cm-1) ν; 3220 cm-
1(NH) , 2961cm-1(CH-ali.), 1624 cm-1(CONH amide); MS (m/z, %) 583 (0.42%) Anal./Calcd.  for C32H29N3O8 :  
C (65.86%), H(4.97%), N (7.20). Found: C (65.86); H (5.01); N, (7.21). 
2.15. 4-(2-((1-(2-acetylhydrazinyl)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-2-oxo-2H-
 chromen-7-yl acetate (19) 
Compound (9; 0.01mol) was heated with acetic anhydride (5 ml) for 3 hrs., the catalytic amount of AcONa was 
added. The solid obtained (19) after cooling, filtered, washed with pet. ether (60/80°C) and recrystallized from 
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abs. ethanol to give compound (19) , as brown crystals; Yield: 65 %; Rf =0.80(CH2-Phe/MeOH=3/1);  
M.P.=185-87°C; IR (KBr cm-1) ν 3323 cm-1(NH), 2961cm-1 (CH-ali.), 1767 cm-1 (C=O),1619cm-1  (CONH 
amide; 1H NMR (300 MHz, Chloroform)  δ= 9.24,8.32 (s,2H,NH-NHNH), 7.62-6.55 (m,9H,CH-arm.), 6.54 
(s,1H,NH-arm.), 4.81 (m,1H,CH-phe.), 3.23 (s,2H,CH2-ali..), 2.84 (d, 2H,CH2-Phe), 2.27,1.99( s,6H,2CH3-
COCH3); MS (m/z,%) 465 (1.61%) Anal./Calcd.for C24H23N3O7:C  (61.91%),  H (4.94%),  N  (9.02%).   Found: 
C (61.93);  H (4.98) ; N, (9.03). 
2.16. 2-(3-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl)thioureido)-3-phenyl-propanoic acid (20) 
L-phe.  (0.01) was stirred  with compound (5) for 6hrs. Then the reaction mixture poured onto ice path. The 
solid obtained  was recrystallized from ethanol to give compound (20) as white crystal; Yield:(85 %); Rf = 0.86 
(CH2-Phe/MeOH=3/1);  M.P.=238-40°C.; IR (KBr cm-1) ν; 3404cm-1(broad band, OH ,NH) ,2960cm-1(CH-ali.), 
1698 cm-1(C=O), 1620 cm-1(CONH amide), 1238 cm-1(C=S).; 1H NMR (300 MHz, Chloroform)  10.28(1H, 
CONHCS), 10.12 (s,1H,OH-COOH),9.41 (s,1H,OHphenyl), 7.47-6.27 (m,9H,CH-arm.), 5.47 (s,1H,NH-
CSNH), 4.70 (m,1H,CH-Phe), 3.03 (s , 2H,CH2-ali.), 2.80 (d, 2H,CH2- Phe); MS (m/z, %) 427 M+1 
(6.81%),Anal./Calcd.  for C21H18N2O6S:  C(59.14%), H(4.22%), N(6.57%). Found: C (59.15); H (4.25); N, 
(6.57). 
2.17. Methyl2-(3-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl)thioureido)-3-phenylpropanoate (21) 
The acid (20, 3.98 g., 0.01 mol.) was allowed to react with thionyl chloride (0.01 mol) in presence of methanol, 
using the technique described in the preparation of compounds (8) to give compound (21) which was 
recrystallized  from ethanol, as brown crystal; Yield: 3.50 g (85 %); Rf = 0.89 (CH2-
Phe/MeOH=3/1);M.P.=195-97°C; ν; 3428cm-1(broad band, OH and NH), 2963cm-1(CH-ali.), 1622cm-1 (CONH 
amide); 1H NMR (300 MHz, Chloroform)  10.34(s,1H,CONHCS), 9.45 (s,1H,OHPhenyl), 7.99-6.11 (m,9H,Ar-
H.), 5.40(s,1H,NHCS), 3.92(s,3H, CH3,OCH3), 3.16 (s,2H, CH2-ali.); MS(m/z,%) 440 (16.18%) Anal./Calcd. 
for C22H20N2O6S: C(60.00%), H(4.54%), N  (6.36%).   Found: C (59.99);  H(4.58 ); N(6.36). 
2.18. N-(1-hydrazinyl-1-oxo-3-phenylpropan-2-ylcarbamothioyl)-2-(7-hydroxy-2-oxo-2H-chromen-4-yl) 
 acetamide (22) 
The compound (21 ; 0.01 mol.) was reacted with alcoholic hydrazine hydrate (0.01 mol), the remaining 
procedures as which described in the preparation of the compound (9) which was recrystallized  from ethanol, as 
brown crystal; Yield: (89 %); Rf = 0. 94 (CH2-Phe/MeOH=3/1); M.P= 290-92°C;  IR (KBr cm-1ν; 3408cm-
1(broad band, OH, NH and NH2), 2960cm-1(CH-ali.), 1622cm-1cm-1 (CONH amide), 1239 cm-1(C=S); 1H NMR 
(300 MHz, Chloroform)  11.08(s,1H,NH,CONHCS), 9.82(s,1H.OH), 7.24-6.78 (m,10H,(1H,NH-NHNH2) + 
(9H,CH-arm.), 5.59 (s,H, NH-CSNH),5.69(s,2H,NH2), 3.97(s,1H,CH-Phe), 3.07(2H,CH2-ali.), 2.79 ( 2H,CH2- 
Phe); MS (m/z, %) 440 (0.07%) Anal. /Calcd. for C21H20N4O5S: C (57.25%),  H(4.54%),N (12.72%).   
Found: C (57.26); H (4.58); N, (12.72).  
2.19. Pharmacological activity 
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Swiss albino mice were divided into 26 groups (n=5). All the groups were injected with Ehrlich Ascites 
Carcinoma (EAC) cells (0.2 ml of 2×106 cells/mouse) intraperitoneally and   intramuscularly in the thigh of 
each recipient mouse  except the normal group, This was taken as day zero, the normal saline and tween (0.2 ml 
/mouse/day) were administered to normal and EAC control groups, the compounds (7,8, 11,13, and 20) and 
standard drug Dose (50 µg/kg/day) were administered in groups (4,5) respectively for 9 days  intraperitoneally, 
after the administration of last dose followed by 24 hrs. Fasting 3 mice form each group was sacrificed for the 
study of antitumor activity. 
2.20.1. Drug Preparation: Preparation and Administration of Doses 
Solution of tested compounds (7,8, 11,13, and 20) were prepared in normal saline. The required volume was 
emulsified in distilled water by using Twin 80 (0.5% of the total volume). The emulsion was prepared in such a 
way that the required daily dose was contained in 0.2mL of the emulsion. 0.2mL of this emulsion was 
administered to each mouse intraperitoneally, daily from day 0 to 9. 
2.20.2. Tumor Transplantation  
Ehrlich’s Ascites Carcinoma was maintained by serial transplantation from tumor bearing Swiss Albino mice. 
EAC cells were obtained from donor mice (Swiss albino) of 18–20 g body weight and suspended in sterile 
isotonic saline. A fixed number of viable cells usually (2×106 cells/20 g body weight) were injected 
intramuscularly in the thigh of each recipient mouse [31]. 
2.20.3. Body Weight 
Animals were weighted on every other day throughout the period of the experiment. 
2.20.4. Solid Tumor Volume and Tumor Growth Inhibition 
Antitumor effects for the different treatments were evaluated by tumor growth inhibition. Tumors were 
measured individually using a caliper. Tumor volume was determined by the following equation [32]: 
Tumor Volume = (Width2 x length)/2 
The percent tumor growth inhibition was calculated on day13 by comparing the average values of treated 
groupsthat of tumor bearing control group. Tumor growth in saline. Treated control animals was taken to be 
100% [33]. 
3. Result Discussion 
3.1. Chemistry 
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The synthetic routes to obtain the target compounds 1-22 were depicted in (Schemes 1-6). The starting 
material 2 was prepared as mentioned by elhenawy et al [30] (Scheme 1), which reacted with L-phenyl alanine (L-
Phe.), and L-Phe. derivative 3 was formed. The presence COOH proton  (δH=10.40 ppm) for 1HNMR data, 
characterized the structure. The isothiocyanate derivative 5 was prepared by the reaction of acid chloride 2 with 
ammonium thiocyanate via intermediate 4 (Scheme 1). 
NCS
OO OH
-
O
OO OH
Cl
(4)
(5)
NCS
NH4+
O
OO OH
O
HO
O
OO OH
Cl
(Scheme 1)
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The free acid derivative 3 undergoing SN2 mechanism, and give the corresponding acid chloride 6. The 
sulphanilamide was reacted with compound 6, to give the sulfanilamide derivative 7, which supported by IR 
data, due to the appearance of characteristic sulfonamide bands at (1335,1230 cm-1). Disappearance of 
characteristic peak (δH=10.40) for COOH proton of compound 3, it is evidence for esterified the acid 3 to 
corresponding methyl ester derivative 8, and was hydrazonlized to corresponding hydrazide derivative 9 
(Scheme 2).   
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The compound 10 was obtained by formylation of hydrazide 9, which  acylated with acetic anhydride, which 
gave 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-(1-(5-methyl-1,3,4-oxadiazol-2-yl)-2-phenyl-ethyl)acetamide 
(11) in 70% yield. The compound 9 undergoing cyclization reaction with L-Phe in presence Conc. H2SO4, and 
gaveN-(4-(5-(1-amino-2-phenyl-ethyl)-1,3,4-oxadiazol-2-yl)phenyl)-2-(7-hydroxy-2-oxo-2H-chromen-4-yl) 
acetamide (12). The compound 9  was reacted with NH4SCN  in catalytic amount of HCl to give thiourea 
derivative 13 in 80% yield (Scheme 3). 
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The CS2 was reacted with compound 9, and led to formation thion 15 or thiol 16 derivatives via salt formation 
intermediate 14, the disappearance peak of thiol group in spectral data led to preferred the formation of thion 
derivative 15 in 75 % yield (Scheme 4).  
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The compound 9 was condensed with different aromatic aldehydes, and afforded the corresponding Schiff¨s  
bases 17a-c, which undergoing cyclization reaction  with acetic anhydride to led formation oxadizole derivatives 
18a-c,). The disappearance of CH    N and OH phenyl peaks of 1HNMR spectrum for Schiff¨s  bases 17a-c, 
confirmed its structures18a-c (Scheme5). The 4-(2-(1-(2-acetyl-hydrazinyl)-1-oxo-3-phenylpropan-2-ylamino)-
2-oxoethyl)-2-oxo-2H-chromen-7-ylacetate (19) was obtained by acylated with acetic anhydride with fused 
sodium acetate, which confirmed with disappearance OH aromatic proton (δH=8.74)  for  hydrazide 9 (Scheme 
5).   
(Scheme 5)
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Thiourido derivative  20 was prepared by coupling of compound 5 with L-Phe, the Thiourido free acid 20 was 
methylated with thionyl chloride via formation acid chloride intermediate to give methyl ester derivative 21, the 
disappearance of peak (δH=10.12) of COOH proton for acid 20, and appearance of 3H proton Of OCH3 at 
(δH=3.92), which confirmed the proposed molecular structure 21. The methyl ester derivative 21 was 
hydrazonolysis and exhibited hydrazide derivative 22 in good yield 89%(Scheme 6). 
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3.2. Pharmacology 
3.2.1. Ehrlich Tumor (Solid) 
The antitumor activity of tested compounds (7,8, 11,13, and 20) were assayed by observation of various 
parameters like Body weight of animals, tumor volume, inhibition tumor growth [35,36] . 
3.2.2. The body weights 
The average weight loss of tested compounds (7,8, 11,13, and 20) were observed against untreated (table 1). The 
data showed that, the compounds (20) showed higher average weight loss (20.5±0.25) upon reference drug 
(DOX) mice group (21.85±0.25), the rest tested members have lower observed average weight change between 
untreated groups (table1). 
Table 1: Average weights and tumor inhibition of ehrlich solid tumor after treatment  compounds (7,8, 11,13  
   and 20). 
Values are expressed as Mean ± SEM and, p ≤ 0.05 indicates the level of statistical significance as compared 
with control. Treatments show highly significant deference at pr>0.0001, the letters (a-f) represents statistically 
significant 
Treatment Body weight of animal on days (g) day 13 
day (0) Day 5 day 9 Avg.  
body wt.(g) 
Avg. tumor 
 volume  
%Tumor growth 
inhibition 
Mortality 
normal 20.2±0.25e 21.6±0.25ed 22.8±0.25b 23.2±0.16a - - 0/5 
untreated 20.9±0.25e 21.4±0.25e 22.2±0.25c 23.0±0.07ed 1.8±0.09a - 0/5 
Dox 23±0.25b 22.4±0.07c 21.85±0.25d 20.4±0.25f 0.4±0.09e 79.04 0/5 
7 21.9±0.07d 22.8±0.12c 23.2±0.25b 23.5±0.16cd 1.5±0.09ab 56.6 0/5 
8 23.5±0.25c 23.8±0.12c 22.5±0.25c - 1.6±0.09d 40.7 1/5 
11 23.6±0.25c 23.0±0.25b 23.7±0.25b 25.7±0.16c 1.6±0.09ab 13.9 2/5 
13 24.4±0.25c 23.5±0.12b 23.3±0.25b 24.6±0.16b 1.7±0.09cd 31.1 0/5 
20 20.5±0.25f 21.2±0.25e 22.9±0.07b 20.5±0.25f 0.5±0.09e 70.5 0/5 
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3.2.3. Solid Tumor Volume: 
 The average tumor volume calculated on day 13 of tested compounds (7,8, 11,13, and 20) in compared with 
untreated control (table 1), and reference drug (Dox). From (table1), all members were exhibited decreasing 
average tumor volume in order 20<7<8<13<20 in range (~0.5-1.7). 
3.2.1. Structure activity relationship 
The antitumor activity of tested compounds (7,8, 11,13, and 20) were examined in vitro of mice, using the 
following parameters, body weight of animals, tumor volume, and tumor growth inhibition. The above data 
showed that, the member containing  thiourea L-phenylalanine methyl ester   moiety 20  showed highest 
inhibition potency (70%), the compounds have sulfonamide 7 and amino acid methyl ester fragments 8   showed 
moderate inhibition potency (56.6 and 40 %), respectively, the other members showed lower inhibition potency, 
(table1). 
3.3. Molecular Modeling studies 
3.3.1. Conformational analysis 
In trying to achieve better insight of the molecular structure, due to  presence chiral center for the synthesized 
compounds (3-13,15,17a,18a,19-22), which led to existence optical isomerism’s for its compounds (3-
13,15,17a,18a,19-22). The optimization geometry  was performed in vacuo with PM3 semi-empirical 
Hamiltonian molecular orbital calculation MOPAC7 package [34], the conformational analysis of the target 
compounds  have been performed to prefer most stable form of stereoisomers using the PM3 (calculations  in  
vacuo,  bond  dipole option for electrostatics, PolakeRibiere algorithm, RMS gradient of 0.01 kcal/ mol) for all 
synthesized compounds (3-13,15,17a,18a,19-22, (table 2). In addition, the computed molecular parameters, total 
energy, electronic energy, heat of formation, the highest occupied molecular orbital (HOMO) energies, the 
lowest unoccupied molecular orbital (LUMO) energies and the dipole moment for studied compounds were 
calculated (table 2). The calculated molecular parameters (table 2) showed, (L) forms have most stable 
structures (3-13,15,17a,18a, 19-22) which may be explained by slightly reducing calculated energy for (L) 
forms over (D) forms for (3-13,15,17a,18a,19-22). The benzocoumarine rings arranged in or coplanar   modes 
with L-Phe moieties (3-13,15,17a,18a,19-22), (table2). 
3.3.2. Docking studies 
COX protein are known with two isoforms: COX-1 and COX-2. The COX-1 produced prostaglandins, and 
expressed in most tissues; and COX-2, is responsible for the increasing production of prostaglandins during 
process of inﬂammation, which is induced by endotoxins, cytokines and mitogens in inﬂammatory cells [35]. 
Recently, analysis the X-ray of COX-2  active site  showed that,  the negative charge of the tetrahedral 
intermediate was stabilized through  coordinated COOH-arachidonic with Tyr385and Ser-530, as well as the 
action of NSAIDs[36]. So, Tyr-385 and Ser-530 have importance structural and functional site for chelating 
ligand [37]. Molecular docking of the synthesized compounds 7,8,11,13 and 20 into the active site of COX-2 
performed, in order to discover biological data on a structural basis, through rationalized ligand–protein 
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interaction behavior. All calculations for docking experiment preformed with MOE 2015.10 [38]. The tested 
compounds were evaluated in silico (docking), using X-ray crystal structures and COX2 (ID: 1PXX) [34] 
complexes with reference inhibitor.  
Table 2: The optimized calculations energies for most stable steroisomer at PM3 molecular orbital for (3-13,15, 
  17a,18a,19-22): 
Cpd E HF IP HOMO LUMO µ 
3 -134034.73 -168.80 8.96 -8.96 -1.09 5.56 
6 -130228.95 -121.66 9.16 -9.16 -0.87 4.52 
7 -137635.72 -183.02 9.07 -9.03 -1.21 4.07 
8 -144153.28 -157.35 9.65 -9.65 -1.30 9.07 
9 -151554.33 -209.68 9.18 -9.18 -1.13 7.76 
10 -123068.74 -44.05 9.20 -9.20 -1.22 1.81 
11 -130459.84 -86.10 9.19 -9.20 -1.02 6.93 
12 -128821.32 -33.25 8.95 -8.93 -1.10 8.59 
13 -136217.69 -118.38 9.20 -9.20 -1.09 3.04 
15 -149838.89 1.78 9.21 -9.21 -1.05 4.85 
17a -164621.2 -115.77 8.98 -8.98 -1.01 4.60 
18a -150486.83 -49.54 8.18 -8.17 -1.20 2.07 
19 -149196.3 -90.62 8.78 -8.78 -1.05 7.28 
20 -146045.95 -41.43 8.85 -8.85 -0.81 8.62 
21 -177024.5 -134.22 9.29 -9.29 -1.32 4.16 
22 -174357.33 -106.50 9.36 -9.36 -1.08 5.13 
E: Total energy (kcal/mol)., HF: Heat of formation (kcal/mol),IP: Ionization potential energy(kcal/mol), 
HOMO: Highest Occupied Molecular Orbital(eV), LUMO: Lowest Occupied Molecular Orbital(eV), µ: Dipole 
moment(Deby). 
The tested compounds docked into COX-2active site. The active site of the enzyme was defined to include 
residues within a 10.0 Å radius to any of the inhibitor atoms. MOE scoring function of the most stable docking 
model for tested compounds applied to evaluate the binding affinities between the inhibitors with (COX) active 
site, (Table 3). The minimization energy preformed for complexes (inhibitor-active site) with anMMFF94 force 
field [39] until the gradient convergence reached to 0.05 kcal/mol. The most active compound 20 docked 
successfully into the COX-2 active site, and compared with reference inhibitor (diclofenac). the compound 20 
was exhibited highest binding score -15.13 Kcal/mol. (table 3).  
3.3.3. Quantum Structures activity relationships 
In order to get a deeper insight into  the  nature  and  type  of  interactions of docked compounds 7,8,11,13 and 
20,  the  complexes  between  each compound and COX-2 receptor were visualized.  The H bond interactions 
playing an important role in the structure and function of biological molecules. The current ligand-receptor 
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interactions were analyzed on the basis of  H bonding. In order to reduce the complexity, hydrophobic and π-
cation interactions (>6Å) are not shown in (Figure 1). 
Table 3: Docking energy scores (kcal/mol) derived from the MOE for new isolated ligands (7,8,11,13,20). 
Cpd. dG Int. H.B. Eele Evdw 
7 -14.58 34.92 -93.88 -3.59 1.27 
8 -13.53 84.77 -51.65 -4.10 1.73 
9 -14.52 -14.36 -50.41 1.74 1.05 
11 -14.81 85.84 -87.83 -4.38 0.72 
13 -14.13 68.04 -102.71 -3.87 1.56 
15 -12.16 62.39 -44.47 -2.3 3.44 
20 -15.13 80.23 -69.3 -1.45 0.97 
d.G.: free binding energy of the ligand from a given conformer, Int.: affinity binding energy of hydrogen bond  
interaction with receptor, H.B.: Hydrogen bonding energy between protein and ligand.Eele: the electrostatic 
interaction with the receptor, Evdw: van der Waals  energies between the ligand and the receptor.  
 
 
 
Figure1: The most active compound 20 were Docked into the active site of COX-2, using MOE tool, H- bonds 
are in blue. 
The highest binding score member is 20, exhibited important two hydrogen interactions with binding site 
through L-phe.-OMe fragment, and stabilized in binding pocket by adjusting its  phenyl ring of L-Phe  and 
coumarin ring  in Parallel mode with Tyr-385. The compound 20 was stabilized with itself by arranged of 
phenyl ring with coumarin ring in coplanar position, (Figure.1). Furthermore, The results obtained clearly 
revealed that, the amino acid  residues  close  to  the  reference  molecule are mostly the same as observed in the 
tested compounds (Figure 1). The higher binding process interaction observed in 20 with COX-2,  indicated 
that, the compounds 20 act as selective inhibitors against COX-2, this may be explained, the presence of 
hydrophobic amino acid in the synthesized compounds.  
3.3.4. ADMET Profile 
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Oral   bioavailability   was   considered   to   play   an   important   role   in   the development   of   bioactive   
molecules   as   therapeutic   agents.   Many   potential therapeutic agents fail to reach the clinic, because of their 
ADMET Factors.  Therefore, a  computational  study  for  prediction  of  ADMET  properties  of  the molecules  
(3-13,15,17a,18a,19-22) were  performed,  by  the  determination  of topological polar surface area (TPSA), a 
calculated  percent absorption (%ABS)[40], and  Lipinski  rules  [41].  In  addition,  the  total  polar  surface  
area  (TPSA)  is  another key  property  linked  to  drug  bioavailability,  the  passively  absorbed  molecules  
with (TPSA>140)  have  low  oral  bioavailability  [42].  All calculated  descriptors  were performed  using  
MOE  Package  [38],  and  their  results  were  disclosed  in  (Table 4). Our results revealed  that,  the  CLogP  
(factor  of  the  lipophilicity  [43]  were  less  than 5.0,  hydrogen  bond  acceptors  between  (7-10),  hydrogen  
bond  donors  between  (1-5),  these  data  showed these  compounds fulfill Lipinski’s rule. Also, the absorption 
percent in ranged between (~ 50-86%).  The HOMO and LUMO of a molecule play important roles in 
intermolecular interactions [44], through the  interaction  between  the  HOMO  of  the  drug  with  the LUMO 
of the receptor and vise versa. The interactions were stabilized inversely with energy  gap  between  the  
interacting  orbitals.  Increasing HOMO energy  and decreasing  LUMO  energy  in  the  drug  molecules  led  to  
enhancement  stabilizing interactions, and hence, binding to the receptor.  
Table 4: Pharmacokinetic parameters important for good oral bioavailability of compounds (3-13,15, 
 17a,18a,19-22): 
CPD HBD HBA LogP V TPSA %ABS Log S ∆E 
3 2 7 2.63 0 101.93 73.83 -4.67 8.39 
6 3 10 1.88 0 139.89 60.73 -5.45 8.29 
7 3 8 4.80 0 141.34 60.24 -6.64 7.50 
8 4 9 1.64 0 133.83 62.83 -4.74 8.32 
9 3 10 1.88 0 139.89 60.73 -5.45 8.29 
10 5 10 2.07 0 164.89 52.11 -6.49 8.43 
11 2 7 2.63 0 101.93 73.83 -4.67 8.39 
12 5 8 1.22 0 130.75 63.89 -4.53 8.53 
13 3 8 2.52 0 146.05 61.14 -6.40 8.25 
15 5 10 3.90 0 157.55 86.73 -7.96 7.09 
17a 3 10 2.05 0 139.90 52.48 -6.80 7.76 
18a 4 10 1.75 1 160.13 55.12 -7.47 7.97 
19 3 8 4.97 0 141.34 50.67 -7.88 7.09 
20 3 8 2.52 0 146.05 69.14 -6.40 8.25 
21 5 10 2.24 1 164.89 98.53 -6.30 8.53 
22 4 9 4.93 1 137.32 61.85 -6.27 8.38 
TPSA: Polar surface area (A°2),%ABS: Absorption percentage, Vol: Volume (A3), HBA: Number of hydrogen 
bond acceptor, HBD: Number of hydrogen bond donor,  V: Number of violation from Lipinski’s rule of five., 
Log P: Calculated lipophilicity., Log S: Solubility parameter, ∆E: Energy Gaps(eV). 
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3.3.5. Prediction of blood–brain barrier permeability  
Blood–brain  barrier  (BBB)  permeability,  is  a  one  of  the  most  important challenges in the pharmacology of 
CNS active drugs. Many drugs have limited usage and fail to pass the clinical trials, due to failure penetration of 
CNS .  In  silico  (Table  5),  the  pharmakinetic  parameters  were  calculated  for  most active compound 20, 
using ADME-T algorthim, and deﬁned human intestinal absorption (HIA) model [45,46], which predicted that, 
the compounds should be able to  transported    across    the  intestinal  epithelium,  which  probably  have  high  
affinity binding  to the plasma proteins, and may be passed  through  the blood-brain barrier, and it is necessary 
for ability drug  transported  throughout  the  body. In general, these  data  (table 5)  suggested  that,  no  marked  
health  effects observed for rodent toxicity profiles, among the most active compound 20, its compound is a 
good ability transport against BBB,  good activity for CNS can  be  used as  a  good oral bioavailability. 
Table 5: The prediction of blood brain barrier most active compounds 20. 
ADME-Tox 20 
LogBBB (  Blood-brain barrier.) 0.048 
PPB% (Plasma protein binding) 94.36 
LD50 rat/mouse(mg kg-1, oral) 500/590 
LD50 rat/mouse(mg kg-1, intraperitoneal) 310/360 
LD50 mouse(mg kg-1, intravenous) 32 
LD50 mouse(mg kg-1, subcutaneous) 350 
Ames test (genotoxicity, %) 0.32 
Prob. of blood effect 0.42 
Prob. of cardiovascular System 0.84 
Prob. of gastrointestinal System 0.90 
Prob. of kidney effect 0.82 
Prob. of liver effect 0.41 
Prob. of lung effect 0.52 
 
4. Conclusion 
The present work aims to synthesis some novel NSAIDs containing coumarin nucleus. The synthesized 
compounds were characterized by different spectral data (IR, 1HNMR). The antitumor activity of tested 
compounds (7,8, 11,13,19b and 20) were examined in vitro against Ehrlich solid  carcinoma (EAC) tumor 
model in Swiss albino mice on dose 50µg , using the following parameters, body weight of animals, tumor 
volume, and tumor growth inhibition. The data showed that, introducing thiourea free acid fragment 20 
enhancements antitumor activity than reference drug (DOX).  The optimization geometries for compounds 
containing L-Phe., showed that, the L- isomers are most stable form for isolated compounds 3-
13,15,17a,18a,19-22.  The molecular docking simulations into the  active  site  of  COX-2  showed  that,   some  
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compounds  (7,8, 11,13, and 20) suitable  inhibitor  against COX-2,  and  can  used  as  New class of NSAIDs. 
The ADMET profiles in silico showed that, these compound are good oral bioavailability, and the most active 
compound 20  is CNS active agent without marked  health effects observed  for rodent toxicity. On the light of 
these data, we think that, this compound may be used new class NSAIDs as candidate anticancer drug with 
some modification of this structure.  
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